The Evolving Role of PSMA-PET/CT in Prostate Cancer Management: an Umbrella Review of Diagnostic Restaging, Therapeutic Redirection, and Survival Impact

Abstract

Purpose of Review

This review explores the clinical applications of PSMA-PET/CT in patients with intermediate to high-risk prostate cancer, focusing on its role in diagnostic reassessment, therapeutic redirection, and potential survival benefits. By evaluating its translational pathway, we aim to provide a structured analysis of its impact on patient management and treatment outcomes.

Recent Findings

Prostate cancer remains a significant health challenge, and advancements in imaging techniques such as PSMA-PET/CT have shown promise in improving diagnostic accuracy and guiding treatment decisions. Emerging evidence highlights its superior sensitivity and specificity compared to conventional imaging, facilitating better staging, detection of metastases, and therapy selection. However, challenges persist in standardizing clinical applications, integrating findings into treatment guidelines, and addressing economic considerations.

Summary

This review synthesizes the latest research findings and cost-effectiveness analyses to establish a comprehensive translational framework for PSMA-PET/CT in prostate cancer management. By consolidating diverse evidence, we aim to provide the medical community with clearer insights into its clinical utility, address ongoing controversies, and propose strategies to minimize treatment risks. The conclusions drawn from this study aspire to refine treatment protocols and enhance clinical outcomes for patients with this prevalent malignancy.

Introduction

Prostate cancer (PCa) stands as one of the most prevalent malignancies among men [1], particularly affecting those classified as intermediate to high-risk patients [2, 3]. The accurate staging and treatment selection for these patients are critical for improving prognosis and enhancing survival outcomes. In recent years, the introduction of prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT) has emerged as a significant advancement in imaging technology, demonstrating superior sensitivity and specificity compared to conventional imaging methods for the staging of prostate cancer, which showing 92% diagnostic accuracy in detecting nodal/distant metastases (vs. 65% for conventional imaging) in prospective trials [4], with sensitivity/specificity reaching 98%/96% for bone lesions [5], while reducing radiation exposure by 56% [4]. These advancements are further supported by systematic reviews comparing its performance across 65 studies [6]. However, the effective translation of PSMA-PET/CT into clinical practice remains a challenge that necessitates thorough exploration. This review aims to systematically analyze the role of PSMA-PET/CT within the clinical pathway of prostate cancer, highlighting innovative changes and potential clinical benefits it brings to patient management.

PSMA-PET/CT imaging has revolutionized the approach to diagnosing and staging prostate cancer. Traditional imaging modalities, such as bone scans and CT scans, have limitations in sensitivity, particularly for detecting metastatic disease. For example, PSMA-PET/CT can more accurately identify locoregional lymph node metastases and distant metastases, thereby optimizing clinical staging and treatment planning for patients [7]. PSMA-PET/CT utilizes a radioligand that specifically targets the PSMA, which is highly expressed in prostate cancer cells, thereby enhancing the detection of both local and distant metastases. Studies have shown that PSMA-PET/CT can identify metastatic lesions that may be missed by conventional imaging techniques, leading to changes in treatment strategies for a significant proportion of patients [8]. PSMA-PET/CT achieves high-sensitivity imaging through radioligands targeting the prostate-specific membrane antigen (PSMA), a mechanism widely supported in the literature. PSMA is highly expressed on the surface of prostate cancer cells, and radioligands (e.g., ⁶⁸Ga- or 18 F-labeled PSMA inhibitors) specifically bind to this antigen, thereby enhancing the detection of both local and distant metastatic lesions [9, 10]. For example, a study in high-risk prostate cancer patients demonstrated that [18 F] PSMA-PET/CT exhibited superior sensitivity compared to conventional bone scans (BS) in detecting bone metastases, altering the CHAARTED risk stratification in 12.8% of patients and subsequently influencing treatment decisions [11]. Regarding the detection of metastases missed by conventional imaging, studies show that even in biochemical recurrence patients with low PSA levels (e.g., 0.1–0.5 ng/mL), the lesion detection rate of [18 F] PSMA-1007 PET remains 66.7%, with detection rates increasing significantly as PSA rises (reaching 100% when PSA > 1.0 ng/mL) [12]. Furthermore, PSMA-PET/CT can identify rare metastatic sites (e.g., brain, adrenal glands, penis, and orbit), which are easily overlooked on conventional CT or bone scans [13].In terms of changes to treatment strategies, approximately 20% of patients had their treatment plans adjusted based on PSMA-PET/CT findings, including shifts from observation to salvage radiotherapy, lymph node dissection, or systemic therapy [10, 11]. These adjustments stem from PSMA-PET/CT’s precise assessment of tumor burden and distribution, such as detecting pelvic lymph node metastases or oligometastatic lesions missed by conventional imaging, thereby providing a basis for metastasis-directed therapy (MDT) [9, 10].

Moreover, PSMA-PET/CT has shown promise in the context of biochemical recurrence, where traditional imaging often fails to localize the source of rising prostate-specific antigen (PSA) levels. The high sensitivity of PSMA-PET/CT in detecting recurrent disease can lead to timely interventions that can significantly impact patient outcomes. For example, a study involving 24 biochemical recurrence (BCR) patients with low prostate-specific antigen (PSA < 2.0 ng/mL) demonstrated that 18 F-DCFPyL PET/CT using 2-mm voxel reconstruction detected more lesions (median 2 vs. 1, P = 0.008) compared to standard 4-mm reconstruction. Individual reader positivity rates also increased from 65.6 to 75.0% (P = 0.014) with advanced reconstruction [14]. Although interobserver agreement did not significantly improve (75.7% vs. 80.6–84.7%, P = 0.08–0.25), this enhanced sensitivity may facilitate earlier targeted interventions. Another study directly demonstrated PSMA-PET/CT’s role in altering treatment strategies. Among 12 BCR patients, ⁶⁸Ga-PSMA-PET/CT detected mesenteric lymph node metastases, prompting treatment adjustments in all cases: 58.3% (7/12) initiated androgen deprivation therapy (ADT), 25% (3/12) received combined salvage radiotherapy, and 8.3% (1/12) started chemotherapy. Follow-up revealed a median PSA decline from 5.39 ng/mL to 2.05 ng/mL post-treatment, with 75% (6/8) of patients showing markedly reduced PSMA uptake in lesions [15]. This highlights PSMA-PET/CT’s precision in guiding personalized therapeutic modifications based on accurate disease localization. These capability underscores the importance of integrating PSMA-PET/CT into the clinical workflow for prostate cancer management, particularly for patients who exhibit biochemical recurrence post-treatment.

Despite the advantages of PSMA-PET/CT, challenges remain in its widespread adoption in clinical practice. Variability in access to this advanced imaging modality, along with the need for standardized protocols for interpretation and reporting, can hinder its implementation. Studies highlight significant disparities in accessibility to PSMA-PET/CT across healthcare institutions, particularly in resource-limited regions where this technology has not yet been incorporated into routine clinical pathways [16]. And this study reports the review of 26 studies revealed substantial heterogeneity in defining PSMA-PET/CT-positive lesions, with interobserver variability reaching 15–30% for small lesions (< 5 mm) and those with low PSMA expression. Furthermore, the interpretation of PSMA-PET/CT results can be complicated by the potential for false positives due to PSMA expression in non-prostatic tissues, necessitating careful consideration and additional diagnostic workup in certain cases [17]. To address these challenges, ongoing efforts to develop standardized reporting frameworks, such as the PSMA Reporting and Data System (PSMA-RADS), aim to improve communication between radiologists and referring physicians, ensuring that the information derived from PSMA-PET/CT is utilized effectively in clinical decision-making [18].

The integration of PSMA-PET/CT into clinical pathways for prostate cancer is not merely a diagnostic advancement; it represents a paradigm shift in how patients are managed throughout their treatment journey. By facilitating more accurate staging, guiding treatment selection, and improving the monitoring of disease recurrence, PSMA-PET/CT has the potential to enhance survival outcomes and quality of life for patients with prostate cancer. As the body of evidence supporting its use continues to grow, it is imperative for healthcare systems to prioritize the incorporation of PSMA-PET/CT into standard practice, ensuring that patients benefit from the latest advancements in cancer imaging and management.

In conclusion, the role of PSMA-PET/CT in the clinical management of prostate cancer is multifaceted, encompassing improved diagnostic accuracy, informed treatment decisions, and enhanced patient outcomes. The ongoing research and clinical trials will further elucidate the optimal utilization of this technology in various stages of prostate cancer, solidifying its place as a cornerstone in the management of this prevalent malignancy.

Technical Background of PSMA-PET/CT

Biological Characteristics of PSMA

Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is overexpressed in prostate cancer cells, making it a significant target for diagnostic imaging and therapeutic interventions. Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography (PSMA-PET/CT) is a cutting-edge imaging modality that leverages the unique expression of PSMA, a protein overexpressed in prostate cancer cells, to enhance the detection of prostate cancer and its metastases. The technology utilizes radiolabeled PSMA ligands (e.g., ⁶⁸Ga-PSMA-11, ¹⁸F-PSMA-1007) that bind specifically to PSMA on prostate cancer cells, enabling high-sensitivity detection via PET imaging [19, 20]. ⁶⁸Ga-PSMA-11 has been approved by the FDA and EMA as a standard tracer for clinical use [19]. This binding allows for the visualization of cancerous tissues through positron emission tomography, combined with the anatomical detail provided by computed tomography. Moreover, PSMA expression levels correlate with tumor aggressiveness, making it a valuable biomarker for assessing disease progression and treatment response [21].

Advances in PET/CT Imaging Technology

The introduction of prostate-specific membrane antigen (PSMA)-PET/CT has fundamentally transformed imaging paradigms for prostate cancer. Conventional imaging techniques (e.g., CT, MRI, and bone scans) exhibit limitations in detecting micrometastatic disease, such as identifying only ~ 50% of lymph node metastases and demonstrating insufficient sensitivity for bone metastases, potentially leading to incorrect staging in 20-30% of patients [22]. In contrast, PSMA-PET/CT integrates functional imaging via PSMA-targeted molecular probes (e.g., ⁶⁸Ga-PSMA-11) with anatomical localization, achieving detection sensitivities of 85-95% for metastatic lesions and specificities exceeding 90% [23, 24]. Notably, even at serum PSA levels as low as 1 ng/mL, PSMA-PET/CT effectively identifies lymph node or bone metastases undetected by conventional imaging [22, 25]. Moreover, the introduction of novel radiotracers, like [18 F]DCFPyL, has further improved diagnostic accuracy and expanded the potential applications of PSMA-PET/CT in both primary staging and the assessment of biochemical recurrence [26]. These advancements have positioned PSMA-PET/CT as the new standard in prostate cancer imaging, influencing clinical decision-making and management strategies.

Factors Influencing Imaging Results

Several factors can significantly impact the results of PSMA-PET/CT imaging, affecting both the sensitivity and specificity of the technique. Patient-related factors, such as body mass index (BMI), hydration status, and prior treatments, can influence the biodistribution of the radiotracer and the overall imaging quality. The elevated proportion of adipose tissue in high-BMI patients may reduce image contrast. Studies indicate that obesity significantly impairs the visualization quality of liver and kidney anatomical structures in ultrasound imaging (β = -0.35, P < 0.0001) [27], this underscores the necessity of adjusting scanning protocols for obese patients to optimize the signal-to-noise ratio (SNR). Although current literature lacks direct investigations into hydration status’s impact on PSMA-PET, nanoparticle drug delivery studies suggest renal clearance efficiency is modulated by hydrodynamic factors [28]. Adequate hydration may accelerate ⁶⁸Ga-PSMA-11 renal excretion, reducing bladder radioactive retention and potentially mitigating pelvic artifact risks, though this hypothesis requires further validation in dedicated PSMA-PET studies. The establishment of standardized interpretation criteria, such as the PSMA Reporting and Data System (PSMA-RADS), aims to mitigate these challenges by providing a structured framework for evaluating PSMA-PET/CT results [29]. In summary, the integration of PSMA-PET/CT into clinical practice for prostate cancer has been driven by its superior biological targeting capabilities, advancements in imaging technology, and the need to address various factors that can influence diagnostic accuracy. As research continues to evolve, the role of PSMA-PET/CT is expected to expand, further enhancing its utility in the management of prostate cancer.

Diagnostic Value of PSMA-PET/CT

Principles and Applications of Imaging Technology

The application of PSMA-PET/CT has expanded significantly since its introduction, particularly in the staging of newly diagnosed prostate cancer, assessment of biochemical recurrence, and evaluation of treatment response. PSMA-PET/CT demonstrates superior accuracy over conventional imaging (CT + bone scan) in detecting pelvic lymph node metastases (sensitivity 85% vs. 38%) and distant metastases (sensitivity 95% vs. 74%) [4, 30]. In a multicenter randomized trial (proPSMA), PSMA-PET/CT altered treatment plans in 28% of high-risk patients, such as shifting from curative-intent surgery to systemic therapy due to occult metastases [4, 6]. PSMA-PET/CT identifies recurrent lesions at lower PSA levels (0.2–0.5 ng/mL) with a detection rate of 45–58%, far exceeding that of conventional imaging (≤ 20%) [7, 31]. RECIP 1.0 criteria (Response Evaluation Criteria in PSMA PET/CT) enable standardized quantification of tumor burden changes. A post-therapy decline in PSMA-positive tumor volume ≥ 30% correlates with improved overall survival in metastatic castration-resistant prostate cancer [32].Thus, PSMA PET/CT playing a crucial role in guiding therapeutic decisions and improving patient outcomes [33].

Comparison with Traditional Imaging Techniques

When compared to traditional imaging techniques such as bone scans, computed tomography (CT), and magnetic resonance imaging (MRI), PSMA-PET/CT offers superior sensitivity and specificity for detecting prostate cancer. Conventional imaging techniques often face challenges in differentiating benign from malignant prostatic lesions, particularly under conditions of low prostate-specific antigen (PSA) levels. For instance, conventional magnetic resonance imaging (MRI) sequences (e.g., T2-weighted imaging), while valuable in detecting prostate cancer, exhibit limited specificity in distinguishing benign hyperplasia from malignant lesions, especially when PSA levels are low [34, 35]. Studies have indicated that at PSA levels < 0.2 ng/mL, the sensitivity of conventional imaging modalities (e.g., bone scans or CT) decreases significantly, whereas prostate-specific membrane antigen (PSMA)-based PET/CT maintains a high positive detection rate (75-100%) [36]. Further analysis demonstrated that the lesion detection rate of PSMA-PET/CT under low PSA conditions (e.g., PSA < 0.01 ng/mL) was 55.6%, while this rate increased to 98.8% when PSA exceeded 0.2 ng/mL [36]. In contrast, PSMA-PET/CT demonstrates significantly higher detection rates for lymph node and distant metastases. For example, the prospective randomized controlled proPSMA trial revealed that PSMA-PET/CT achieved 85% sensitivity and 98% specificity for detecting pelvic lymph node metastases, whereas conventional imaging (CT combined with bone scan) showed only 38% sensitivity and 91% specificity [4]. Furthermore, in detecting distant metastases, PSMA-PET/CT achieved 95% sensitivity and 94% specificity, significantly outperforming conventional imaging’s 74% sensitivity and 87% specificity [4].

In biochemical recurrence patients with low PSA levels (e.g., < 1 ng/mL), PSMA-PET/CT detects lymph node metastases in 50–70% of cases, compared to < 20% detection rates for conventional imaging (CT or MRI) [10, 37]. For bone metastasis detection, PSMA-PET/CT demonstrates superior sensitivity (97–99%) versus 70–80% sensitivity for traditional bone scans, which also carry higher false-positive rates due to misinterpretation of degenerative bone changes [4]. Notably, PSMA-PET/CT can identify micrometastases missed by conventional imaging. A robotic-assisted surgical study demonstrated that PSMA-targeted radioguided techniques intraoperatively localized 11 metastatic lymph nodes (median diameter 3 mm) that were undetected on preoperative ⁶⁸Ga-PSMA-PET/CT [38]. Additionally, current evidence highlights the transformative role of ⁶⁸Ga-PSMA PET/CT in clinical decision-making for prostate cancer, particularly in cases where conventional imaging fails to clarify disease status. Multiple studies demonstrate that PSMA-PET/CT outperforms traditional imaging modalities (e.g., CT, bone scan, or choline PET/CT) with superior sensitivity for detecting lower PSA levels (< 0.5 ng/mL) or smaller metastases, leading to treatment strategy modifications in up to 70% of patients [39–42]. For instance, in nodal staging, PSMA-PET/CT identifies extrapelvic lymph node metastases in 34.5% of cases, prompting cancellation or redirection of planned extended pelvic lymph node dissection (ePLND) to systemic therapy in 70.2% of patients [40]. In biochemical recurrence (BCR), PSMA-PET/CT-negative findings (particularly in low-risk patients) support clinical surveillance over immediate intervention, with a 12-month recurrence-free survival rate of 61.4%, informing personalized follow-up strategies [43]. For metastatic disease diagnosis, PSMA-PET/CT is endorsed as the first-line imaging modality by Dutch multidisciplinary consensus guidelines. It precisely identifies non-regional lymph node metastases (M1a), guiding combination therapies such as androgen deprivation therapy (ADT) with local radiotherapy [42]. Real-world studies further reveal that PSMA-PET/CT optimizes the timing of triple therapy (ADT + chemotherapy + ARPI), demonstrating that concurrent initiation of chemotherapy and ARPI significantly reduces progression risk (HR 0.245) [44].

Although standardized reporting systems for PSMA-PET/CT remain under development, its high specificity (> 95%) in staging, recurrence monitoring, and treatment response assessment has progressively established it as the cornerstone of clinical practice, replacing conventional imaging [41, 45]. These findings collectively underscore PSMA-PET/CT’s pivotal role in enhancing therapeutic precision and reducing unnecessary interventions.

Clinical Application Examples and Data Analysis

Clinical applications of PSMA-PET/CT have been extensively documented, showcasing its effectiveness in various scenarios. For instance, in primary staging, PSMA-PET/CT exhibits superior sensitivity (78%) and specificity compared to conventional imaging (e.g., CT or bone scans), particularly in high-risk prostate cancer patients [46, 47]. Studies indicate that modifying treatment strategies based on PSMA-PET/CT findings (e.g., avoiding unnecessary extended lymph node dissection) can reduce healthcare costs (averaging €674 savings in European countries), though clinicians must consider risks of false-positive misinterpretations (e.g., misclassifying localized lymph node metastases as widespread disease, leading to inappropriate palliative care) [48, 49]. However, its limited sensitivity for seminal vesicle invasion (SVI) assessment (42.29%) underscores the need for complementary imaging or pathological confirmation [46]. Furthermore, the study revealed that among patients who were N0/M0 based on conventional imaging, PSMA-PET/CT identified metastatic disease in a significant percentage, emphasizing its role in refining staging and treatment planning [44]. Another clinical trial highlighted that PSMA-PET/CT not only improved detection rates but also influenced treatment decisions in 61% of patients, leading to a shift from curative to palliative care strategies when appropriate. These findings underscore the importance of PSMA-PET/CT in enhancing diagnostic accuracy and informing clinical management, ultimately contributing to improved patient outcomes and survival rates [50]. In summary, the integration of PSMA-PET/CT into clinical practice represents a significant advancement in the management of prostate cancer, offering enhanced diagnostic capabilities that surpass traditional imaging modalities. Its ability to detect disease at earlier stages and guide treatment decisions underscores the necessity for its continued adoption and further research to optimize its application in various clinical contexts.

Treatment Plan Adjustments

Treatment Decisions Based on PSMA-PET/CT

Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has emerged as a pivotal imaging modality in the management of prostate cancer, particularly in guiding treatment decisions. The enhanced sensitivity and specificity of PSMA-PET/CT compared to conventional imaging techniques have made it the new standard for staging and restaging prostate cancer. Studies indicate that PSMA-PET/CT significantly influences clinical management by providing critical information about tumor localization and metastatic spread, which is essential for tailoring treatment strategies. Compared to conventional imaging (e.g., CT and bone scans), PSMA-PET/CT demonstrates superior detection of lesions at lower PSA levels (< 1 ng/mL) in biochemical recurrence, with sensitivity and specificity improved to 85% and 98%, respectively [4, 39]. For example, the multicenter randomized proPSMA trial reported a diagnostic accuracy of 91% for pelvic lymph node metastasis detection with PSMA-PET/CT, significantly higher than the 59% accuracy of conventional imaging (P < 0.0001) [4]. This capability led to treatment plan modifications in ~ 28% of patients (e.g., abandoning local therapy in favor of systemic treatment) upon identification of occult metastases [31]. Furthermore, the integration of PSMA-PET/CT into the management pathway has been associated with improved patient outcomes, including overall survival and quality of life, owing to more precise treatment targeting.

The decision-making process is further enhanced by the ability of PSMA-PET/CT to provide a comprehensive assessment of disease burden, which is crucial for risk stratification. Standardized uptake values (SUVmax) on PSMA-PET/CT correlate positively with tumor aggressivity. For instance, patients with baseline SUVmax > 10 exhibit significantly lower 3-year progression-free survival (PFS) compared to those with SUVmax ≤ 10 (42% vs. 78%, P < 0.001) [51, 52]. Quantitative metrics like metabolic tumor volume (MTV) and total lesion PSMA (TL-PSMA) further stratify disease burden, with MTV > 20 mL predicting shortened overall survival (OS) (HR = 2.1, P = 0.01) [51]. PSMA-PET/CT is being integrated as an endpoint in clinical trials to accelerate drug development. For example, in trials evaluating PSMA-targeted radioligand therapy (RLT), PSMA-PET guides radiation dose adjustments, combination therapies (e.g., PARP inhibitors), and disease control rate assessments [53]. Standardized reporting frameworks (e.g., PSMA-RADS) improve imaging interpretation consistency and cross-trial data comparability (inter-observer consistency ICC = 0.91) [54, 55]. Post-treatment PSMA-PET/CT (ePET) can predict survival outcomes. Studies show that patients with new lesions or PSMA tumor volume (PSMA-VOL) progression on ePET had a median OS of 10.7 months, while those without progression did not reach median OS (p = 0.007) [56]. Additionally, the RECIP 1.0 criteria for assessing disease progression on PSMA-PET/CT correlated significantly with OS, supporting its role as a biomarker for treatment response [56]. Moreover, the evolving role of PSMA-PET/CT in clinical trials suggests its potential to redefine treatment paradigms, as ongoing studies are assessing its utility in guiding novel therapeutic agents, including radioligand therapy [29]. As such, the incorporation of PSMA-PET/CT into clinical practice represents a significant advancement in the personalized management of prostate cancer, facilitating more informed and effective treatment decisions.

Early Intervention and Patient Prognosis

The timing of intervention in prostate cancer management is critical, as early treatment has been associated with improved patient prognosis. Current evidence suggests that survival benefits from early intervention are primarily observed in intermediate- to high-risk patient subgroups, with limited overall strength of evidence and potential treatment-related risks. The latest clinical decision aids (e.g., the Navigate platform) recommend integrating personalized risk assessments (such as PSA kinetics and genetic testing) and patient quality-of-life preferences, rather than relying solely on early treatment timing [57]. Large-scale randomized trials (e.g., the ProtecT trial) have shown comparable 10-year overall survival rates (~ 98–99%) between active surveillance and immediate treatment (surgery or radiotherapy) for localized prostate cancer [58]. However, in high-risk patients (e.g., PSA > 20 ng/ml or Gleason score ≥ 8), radical therapies may reduce cancer-specific mortality by 5–10% [59]. Early intervention strategies, particularly in high-risk populations identified through PSMA-PET/CT imaging, can lead to favorable outcomes by addressing the disease before it progresses to advanced stages where treatment options become limited and less effective. Studies have shown that early treatment can reduce the risk of metastasis and improve the likelihood of achieving long-term remission. For instance, patients with high-risk features detected via PSMA-PET/CT may benefit from immediate systemic therapy, which can prevent the progression to castration-resistant prostate cancer [17].

Additionally, the psychological impact of early intervention should not be overlooked; patients who receive timely treatment often report higher satisfaction with their care and improved quality of life, as they are more likely to feel in control of their disease [60]. Furthermore, the role of multidisciplinary teams in facilitating early intervention cannot be understated. Collaborative approaches that involve urologists, medical oncologists, radiologists, and nuclear medicine specialists ensure that patients receive comprehensive evaluations and timely treatment recommendations. This integrated care model not only enhances the decision-making process but also aligns treatment plans with the latest clinical guidelines and evidence-based practices, ultimately improving patient outcomes [21]. Therefore, the emphasis on early intervention in prostate cancer management, supported by advanced imaging techniques like PSMA-PET/CT, represents a paradigm shift towards more proactive and effective treatment strategies.

The Role of Multidisciplinary Collaboration in Treatment Adjustments

Multidisciplinary collaboration is essential in the management of prostate cancer, particularly when it comes to treatment adjustments informed by advanced imaging techniques such as PSMA-PET/CT. The complexity of prostate cancer, with its diverse presentations and treatment responses, necessitates a team approach that integrates various specialties, including urology, medical oncology, radiation oncology, and radiology. This collaborative framework allows for a comprehensive assessment of each patient’s condition, facilitating more informed and personalized treatment decisions [26].The involvement of a multidisciplinary team enhances the ability to interpret PSMA-PET/CT findings accurately and to integrate these insights into clinical practice. For instance, radiologists play a crucial role in identifying lesions and assessing their significance, while oncologists can interpret these findings within the context of the patient’s overall clinical picture, including their treatment history and preferences. This synergy is particularly important in cases where PSMA-PET/CT reveals unexpected findings, such as incidentalomas or atypical metastatic patterns, which may require a reevaluation of the treatment plan [8]. Moreover, multidisciplinary collaboration fosters a culture of continuous learning and adaptation, as team members share insights and experiences from their respective fields. Regular case discussions and tumor board meetings provide opportunities to review complex cases, ensuring that treatment adjustments are based on the most current evidence and best practices. This collaborative approach not only improves patient outcomes but also enhances the overall quality of care by ensuring that treatment plans are comprehensive and well-coordinated [17].

In conclusion, the integration of PSMA-PET/CT into the treatment decision-making process, coupled with early intervention strategies and robust multidisciplinary collaboration, represents a transformative approach in the management of prostate cancer. By prioritizing these elements, healthcare providers can optimize treatment outcomes and improve the quality of life for patients navigating this complex disease.

Comprehensive Analysis of Survival Benefits

Assessment of Cumulative Survival Rate Data

The assessment of cumulative survival rates is crucial in evaluating the effectiveness of various treatment modalities in oncology, particularly in prostate cancer, where survival outcomes are significantly influenced by early detection and intervention strategies. Recent studies have demonstrated that PSMA-PET/CT have markedly improved the accuracy of staging and subsequent treatment planning, leading to enhanced survival rates. A randomized controlled trial in patients with newly diagnosed prostate cancer demonstrated that PSMA-PET/CT offers superior staging sensitivity and accuracy compared to traditional sodium fluoride (NaF)-PET/CT. This imaging advantage may improve progression-free survival (PFS) by enabling precise tumor localization, though final survival data from the study remain under follow-up [61]. Studies have further confirmed that in high-risk prostate cancer (Gleason score 10), patients staged with ⁶⁸Ga-PSMA-PET/CT achieved significantly higher 5-year freedom from biochemical failure (FFBF, 59.2%) and prostate cancer-specific survival (PCSS, 77.0%) compared to those staged with conventional imaging (p < 0.05) [62]. Furthermore, PSMA-PET/CT-guided simultaneous integrated boost (SIB) to the primary tumor improved PCSS and distant metastasis-free survival (DMFS), while combining long-term androgen deprivation therapy (ADT ≥ 18 months) significantly enhanced overall survival (OS) [62]. These findings collectively highlight that PSMA-PET/CT plays a pivotal role in improving tumor control rates and survival outcomes through precise staging and personalized treatment optimization.

Furthermore, the integration of advanced imaging techniques has been shown to facilitate timely therapeutic interventions, thereby enhancing overall survival rates in patients diagnosed with localized prostate cancer. Longitudinal data from existing studies robustly support the survival benefits of PSMA PET/CT-guided treatment strategies in prostate cancer. For example, a retrospective analysis of 100 patients found that ⁶⁸Ga-PSMA PET/CT altered treatment plans in 73% of cases, with hormone-sensitive patients achieving significantly improved 2-year overall survival (OS) after therapy adjustment (95% vs. 81%), demonstrating the direct survival impact of imaging-guided management [63].

Additionally, studies in oligometastatic castration-resistant prostate cancer revealed that PSMA PET/CT-directed metastasis-targeted radiotherapy achieved a median progression-free survival (PFS) of 16.4 months and a 2-year OS of 91.1%, surpassing outcomes with conventional therapies [64]. A multinational study of 5,275 high-risk patients further validated prognostic models based on PSMA PET/CT upstaging probabilities, showing strong predictive power for distant metastasis (C-index 0.69) and cancer-specific mortality (C-index 0.71), indicating that refined staging optimizes treatment intensity and outcomes [65]. Notably, the ongoing phase III PATRON trial (NCT04557501), with a planned enrollment of 776 patients, aims to evaluate the efficacy of PSMA PET/CT-guided radiotherapy/surgical intensification in improving 5-year failure-free survival, potentially providing high-level evidence for survival benefits [66]. Collectively, these data highlight that PSMA PET/CT enhances survival by enabling earlier detection of micrometastases (30–40% higher sensitivity than conventional imaging) [67] and guiding treatment intensification (e.g., expanded radiotherapy fields or metastasis resection) [68, 69], thereby achieving molecular-level disease control and translating into survival advantages. These evidence underscores the importance of utilizing advanced imaging modalities in clinical practice to optimize treatment outcomes and improve survival statistics in patients with prostate cancer.

Correlation Between Survival Benefits and Treatment Optimization

The correlation between survival benefits and treatment optimization is a pivotal aspect of modern oncology, particularly in the context of prostate cancer management. Treatment optimization involves tailoring therapeutic strategies based on individual patient characteristics, tumor biology, and the latest advancements in diagnostic imaging. The advent of PSMA PET/CT has revolutionized the approach to prostate cancer by enabling more precise localization of tumors and metastases, which in turn allows for more targeted and effective treatment regimens [8, 70]. Studies have shown that patients who receive optimized treatment plans—guided by accurate imaging—experience significantly improved survival outcomes compared to those on standard treatment protocols. For example, in hormone-sensitive oligometastatic prostate cancer, imaging technology based on prostate-specific membrane antigen (PSMA) PET can more accurately identify metastatic lesions (with an accuracy of 88%) [71]. After guiding directed treatment of metastases, patients achieve a 5-year progression-free survival rate ranging from 19 to 100%, which is significantly higher than the 16–93% seen with traditional choline PET-guided therapy [71]. In addition, patients in the PSMA PET group had higher androgen deprivation therapy (ADT) progression-free survival rates (48–79%) and local control rates (75–100%) compared to the standard treatment, indicating that image-guided precision treatment can delay disease progression and reduce treatment-related toxicity [71].Imaging technology also plays a crucial role in the radical treatment of localized prostate cancer. High-dose image-guided intensity-modulated radiation therapy (IG-IMRT) combined with prostate marker tracking technology allows high-risk patients to achieve a 5-year PSA relapse-free survival rate of 82.2%, with a distant metastasis rate of only 5%, significantly outperforming traditional radiation therapy survival data. Studies have also shown that patients with Gleason scores of ≥ 8 who receive image-guided radiation therapy can maintain a high survival rate (5-year overall survival of 91.7%), highlighting the importance of imaging technology for dose optimization in high-risk populations [72]. Additionally, the ability to stratify patients based on risk factors using advanced imaging techniques has facilitated the development of personalized treatment plans that maximize therapeutic efficacy while minimizing unnecessary interventions. This tailored approach not only improves survival rates but also enhances the quality of life for patients undergoing treatment for prostate cancer.

Significance of Long-Term Follow-Up Results

Long-term follow-up results are essential for understanding the sustained impact of therapeutic interventions on patient survival and quality of life in prostate cancer management. Recent studies have shown that the high sensitivity of PSMA PET/CT imaging can significantly improve the detection rate of recurrent lesions during continuous monitoring after radical treatment for prostate cancer, particularly at low prostate-specific antigen (PSA) levels (e.g., < 1 ng/mL) [73, 74]. For instance, a Phase III randomized trial (PSMA-SRT) evaluated the effectiveness of PSMA PET/CT-guided salvage radiotherapy (SRT) in patients with postoperative biochemical recurrence and found that this technique altered the treatment plan for approximately 50% of patients, including adjustments to the radiotherapy target area or the addition of androgen deprivation therapy (ADT) [73, 75]. However, although PSMA PET/CT is expected to improve biochemical progression-free survival (with some studies reporting biochemical response rates of 45–94%) [73], there is currently insufficient evidence to confirm a definitive improvement in long-term overall survival [74, 75]. Notably, lesions detected by PSMA PET/CT often extend beyond traditional postoperative radiotherapy targets (e.g., extrapelvic metastases), potentially leading to a shift in treatment strategy from local radiotherapy to systemic therapy [73]. However, whether such adjustments truly improve long-term outcomes requires further data [75]. Currently, prospective studies addressing this issue (e.g., NCT03582774) are expected to complete primary endpoint analyses in 2023–2024, which will provide clearer evidence. Therefore, existing guidelines recommend individualized monitoring based on PSMA PET/CT for patients with biochemical recurrence, while emphasizing the need for long-term follow-up to validate its clinical value [73, 74].

Future Research Directions and Challenges

Current Research Limitations

The application of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in prostate cancer imaging has demonstrated significant advancements in diagnostic accuracy compared to traditional imaging modalities. PSMA PET/CT exhibits high diagnostic accuracy in detecting biochemical recurrence of prostate cancer, even at low PSA levels. However, its role in primary prostate cancer is not yet fully established, indicating that further research is needed to determine its efficacy in early-stage applications [76]. This indicates that the sensitivity of this technique is limited at extremely low PSA levels, which may be attributed to the PSMA expression levels of micrometastases or spatial resolution constraints [77]. In patients with PSA < 1 ng/mL, the detection rate of PSMA PET/CT is 49.6%, with a higher detection rate observed in the PSA 0.5–1.0 ng/mL range. However, its effectiveness is limited when PSA is < 0.5 ng/mL, indicating a potential sensitivity deficiency in the very early stage [78].Moreover, PSMA PET/CT faces challenges in detecting prostate bed recurrence due to high uptake in the bladder and urethra, which may interfere with the identification of local lesions. This could impact its accuracy in detecting early primary tumors or local recurrences [79]. These results shown PSMA PET/CT has certain limitations in detection during the early stages, particularly at low PSA levels, but performs better when PSA ≥ 0.5 ng/mL. However, for detecting very early-stage or local recurrence, multimodal imaging or additional techniques may be required to improve accuracy. Further research is needed to optimize imaging timing and interpretation criteria to enhance its effectiveness in characterizing early disease features.

The Impact of Emerging Technologies on PSMA-PET/CT

Emerging technologies are poised to significantly enhance the capabilities of PSMA-PET/CT in prostate cancer management. Based on current research, 18 F-PSMA-1007 PET/CT has demonstrated significant advantages in detecting prostate cancer lesions at low PSA levels. A comparative study reported that this tracer achieved a 100% detection rate for primary lesions, significantly higher than 67% for 18 F-FDG (P < 0.05) [80]. Additionally, the maximum standardized uptake value (SUVmax) for metastatic lesions reached 10.72, which is 2.4 times that of 18 F-FDG. This high contrast may facilitate the identification of lesions in low-PSA patients [80, 81]. Notably, in biochemical recurrence (BCR) patients, this technique detected 88% of lymph node metastases with a short-axis diameter < 8 mm, suggesting its potential for small lesion detection [81]. Regarding the potential synergy of whole-body PET imaging, a report indicated that the combined use of 64Cu-PSMA and 18 F-PSMA-1007 could provide more comprehensive lesion coverage [82]. Although existing studies do not directly mention whole-body PET systems, 18 F-PSMA-1007’s low renal clearance (with an average SUVmax of only 5.9 in the bladder [83], along with its high spatial resolution (capable of detecting rare metastases such as pulmonary lymphangitic carcinomatosis [84], theoretically allows for extended scan ranges to improve the detection of microlesions. However, several others limitations should be noted: (1) Non-specific bone uptake may lead to a false-positive rate of 18.9% [85]; (2) Benign lesions exhibit high uptake, reaching up to 40% [80]; (3) Low bladder volume may result in increased tracer concentration in urine, affecting pelvic assessments [83]. These factors may increase the risk of misinterpretation in low-PSA patients, necessitating correlation with multiparametric MRI or histopathological validation. Future studies should focus on establishing diagnostic threshold systems for low-PSA populations (< 0.5 ng/mL).

Artificial intelligence (AI) applications in prostate cancer PSMA PET/CT image analysis have significantly improved tumor localization accuracy and enhanced the ability to differentiate between benign and malignant lesions. Studies show that AI algorithms can automate lesion detection and segmentation, reducing human error while integrating multimodal imaging features to optimize the diagnostic process [16, 86]. In terms of tumor localization, AI models such as the automated a PROMISE platform can quickly identify PSMA-high uptake lesions and quantify overall tumor burden. For example, one study showed that the platform detected 1,576 lesions in baseline scans and 1,631 lesions in follow-up scans after treatment (including 35% new lesions), with a consistency of 89.6% with clinical assessment (κ = 0.79), demonstrating its reliability in dynamic monitoring [87]. Additionally, convolutional neural network (CNN)-based models can automatically assess tumor burden in bone metastases. The PET index generated by these models showed moderate correlation with the doctor’s evaluation (average r = 0.69), significantly outperforming traditional SUV threshold methods (average r = 0.49) [88]. For differentiating between benign and malignant lesions, AI can analyze PSMA uptake heterogeneity and lesion morphological features to distinguish between high-grade malignant tumors within the prostate and benign lesions. For example, AI models have shown potential in predicting extra-prostatic extension and distinguishing between metastatic lymph nodes and non-specific uptake [16, 86]. The literature also indicates that AI-enhanced ultra-fast PSMA-PET technology can improve image quality by about 17.9%, significantly increasing lesion detection rates for T, N, and M1a/M1b staging (e.g., N-stage detection rate increased from 27.8 to 46.3%, p < 0.01). However, the sensitivity for low uptake or small lesions (e.g., SUVmax < 10 or diameter < 5 mm) still needs optimization [89].

Additionally, the combination of PSMA-PET/CT with other imaging modalities, such as multiparametric MRI, has been shown to improve diagnostic accuracy, particularly in assessing extraprostatic extension and seminal vesicle invasion. mp-MRI demonstrates higher sensitivity (83% vs. 44%) and specificity (90% vs. 85%) in detecting extra-prostatic extension (EPE), primarily due to its high-resolution ability to identify subtle structural changes in the prostate capsule [90, 91]. In contrast, PSMA-PET/CT helps locate more aggressive lesions by highlighting metabolically active regions of the tumor, indirectly indicating potential EPE risk areas. For instance, Reference 3 found that when both modalities were used together, the sensitivity for EPE detection increased from 55% with mp-MRI alone to 72% (p < 0.05) [31]. Furthermore, PSMA-PET/CT has higher sensitivity for seminal vesicle invasion (SVI) (75% vs. 55%) as it can detect small areas of high PSMA uptake within the seminal vesicles, while mp-MRI offers better specificity when assessing involvement of seminal vesicle anatomy (96% vs. 94%) (Reference 24). When combined, the overall diagnostic accuracy for SVI reaches 89%, significantly higher than using a single modality (p = 0.01) [31]. For improved tumor localization consistency, PSMA-PET/CT alone showed 41.8% consistency with pathological results, while mp-MRI showed 36.4%. However, when both modalities were combined, consistency improved to 72.1% (p < 0.001), especially in distinguishing multifocal tumors and identifying the index lesion [31, 91]. As these technologies continue to evolve, they hold the potential to redefine the landscape of prostate cancer diagnostics and treatment, necessitating ongoing research to evaluate their clinical utility and integration into standard practice.

Summary

In summary, the advent of PSMA-PET/CT imaging for patients with high-risk prostate cancer marks a noteworthy evolution in the areas of staging, treatment modification, and the associated survival advantages of this ailment. This review emphasizes the clinical significance of PSMA-PET/CT, highlighting its capacity to refine the management of prostate cancer through precise detection of disease dissemination and informed treatment planning. This pioneering imaging technique supports a more tailored therapeutic approach, which is increasingly crucial in an era characterized by personalized medicine.

Nonetheless, in light of these encouraging results, it is vital to recognize the current limitations and barriers to the integration of PSMA-PET/CT into everyday clinical practice. Challenges such as the necessity for standardized imaging protocols, discrepancies in the availability of radiotracers, and the urgent need for thorough training of healthcare professionals in interpreting these sophisticated imaging findings must be addressed. Furthermore, while the existing evidence is compelling, it requires further validation through expansive, multicenter trials that can offer a more profound insight into the long-term survival benefits linked to PSMA-PET/CT-guided management.

From a professional standpoint, it is essential to strike a balance among the varied research findings and viewpoints regarding PSMA-PET/CT. While the technology presents significant benefits, it is equally important to contextualize these results within the broader framework of prostate cancer treatment. For example, the incorporation of PSMA-PET/CT into established treatment regimens should be approached with caution, taking into account the variability in patient demographics and the potential risk of an over-reliance on imaging that may overshadow clinical judgment.

Future investigations should not only emphasize the enhancement of imaging methodologies and the refinement of diagnostic pathways but also examine the interplay between PSMA-PET/CT and innovative treatment strategies. This includes the integration of imaging information with advanced therapies, such as androgen receptor blockers and immunotherapy, to further optimize patient outcomes. Additionally, evaluating the cost-effectiveness and the ramifications of the widespread application of PSMA-PET/CT on healthcare resources will be crucial for its sustainable incorporation into standard clinical practice.

Conclusion

In conclusion, while PSMA-PET/CT stands out as an innovative instrument in the management of high-risk prostate cancer, the journey ahead necessitates a multifaceted strategy that fosters collaboration among researchers, clinicians, and policymakers. By addressing existing hurdles, validating long-term advantages, and ensuring the judicious use of this technology, we can amplify its influence on patient care and ultimately improve survival rates for those impacted by prostate cancer. The future trajectory of prostate cancer management hinges on our capability to harness groundbreaking imaging techniques like PSMA-PET/CT while navigating the intricacies of clinical practice and patient-centered care.

Key References

1. Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024). Cancer statistics, 2024. [Journal Article]. CA Cancer J Clin, 74(1), 12–49. doi: 10.3322/caac.21820.

   • This shows prostate cancer has solidified its position as the most prevalent malignancy among men globally, with recent epidemiological studies projecting over 299,010 new cases diagnosed.

2. Chow, K. M., So, W. Z., Lee, H. J., Lee, A., Yap, D., Takwoingi, Y., Chen, K. (2023). Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis. [Journal Article; Meta-Analysis; Review; Systematic Review]. Eur Urol, 84(1), 36–48. doi: 10.1016/j.eururo.2023.03.001.

   • This study, researchers conducted a high-quality systematic review and meta-analysis to compare the diagnostic accuracy of PSMA-PET with conventional imaging modalities (CIM), including multiparametric magnetic resonance imaging (mpMRI), computed tomography (CT), and bone scan (BS), for initial staging in intermediate- to high-risk prostate cancer. The findings revealed that PSMA-PET demonstrated significantly higher sensitivity and specificity than CIM in detecting primary tumors, lymph node metastases, and bone metastases. These results strongly support the recommendation of PSMA-PET as the first-line imaging modality for initial staging of prostate cancer.

3. Sonni, I., Felker, E. R., Lenis, A. T., Sisk, A. E., Bahri, S., Allen-Auerbach, M., Calais, J. (2022). Head-to-Head Comparison of (68)Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial. [Clinical Trial; Journal Article]. J Nucl Med, 63(6), 847–854. doi: 10.2967/jnumed.121.262398.

   • The study results underscore the complementary value of these imaging modalities, suggesting that the combined use of PSMA PET/CT and mpMRI in clinical practice could optimize therapeutic strategy formulation through enhanced diagnostic precision.

4. Miller, S. R., Gonzalez, R. T., Jackson, W. C., Caram, M., Tsao, P. A., Stensland, K., Bryant, A. K. (2025). Rates of PSMA PET Staging and Positivity in Newly Diagnosed Prostate Cancer in a National Health Care System. [Journal Article]. J Nucl Med, 66(1), 75–83. doi: 10.2967/jnumed.124.268555.

   • This study provides critical real-world evidence supporting the clinical implementation of PSMA PET in newly diagnosed prostate cancer patients, validating its significant utility for high-risk disease stratification while underscoring the necessity for refined patient selection criteria in intermediate-risk populations.

5. Bundschuh, R. A., Lütje, S., Bundschuh, L., Lapa, C., Higuchi, T., Hartrampf, P. E.,… Werner, R. A. (2023). High Interobserver Agreement on PSMA PET/CT Even in the Absence of Clinical Data. [Journal Article]. Clin Nucl Med, 48(3), 207–212. doi: 10.1097/RLU.0000000000004524.

   • The PSMA Reporting and Data System (RADS) demonstrated excellent interobserver agreement (intraclass correlation coefficient [ICC] = 0.91), underscoring that structured scoring systems can provide reliable guidance for scan interpretation even in the absence of clinical information.

6. Gondoputro, W., Scheltema, M. J., Blazevski, A., Doan, P., Thompson, J. E., Amin, A., Stricker, P. D. (2022). Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate Cancer. [Journal Article; Research Support, Non-U.S. Gov’t]. J Nucl Med, 63(11), 1659–1664. doi: 10.2967/jnumed.121.263743.

   • This study investigates the safety and feasibility of 99mTc-labeled PSMA robot-assisted radioguided surgery for primary prostate cancer management. The research aimed to enhance intraoperative detection of lymph node metastases during robot-assisted radical prostatectomy (RARP), demonstrating a novel surgical approach that could potentially improve nodal metastasis detection rates and subsequently refine treatment outcomes in PCa patients.

7. Unterrainer, L. M., Hope, T. A., Fendler, W. P., Grogan, T., Ndlovu, H., Armstrong, W., Calais, J. (2025). Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study. [Comparative Study; Journal Article; Multicenter Study]. J Nucl Med, 66(1), 54–60. doi: 10.2967/jnumed.124.268441.

   • The study demonstrated that PSMA PET imaging offers superior sensitivity in disease staging, with staging discrepancies between PSMA-based and conventional imaging classifications significantly impacting therapeutic decision-making pathways.

8. Nikitas, J., Castellanos, R. A., Farolfi, A., Seyedroudbari, A., Kishan, A. U., Nickols, N. G.,… Calais, J. (2024). Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer. [Journal Article]. J Nucl Med, 65(9), 1387–1394. doi: 10.2967/jnumed.124.267922.

   • This study investigates the clinical application of PSMA PET/CT-guided metastasis-directed radiotherapy in oligometastatic castration-resistant prostate cancer patients. The research underscores the technical superiority of PSMA PET/CT in enabling earlier and more precise selection of candidates for metastasis-directed therapies compared to conventional staging methods.

Author Contributions

All authors contributed to the study’s conception and design. LCW and LZW were response to integrated article and write the manuscript. XAW and DLW revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Funding

This study was supported by National Natural Science Foundation of China (NO. 82472857), Sixth Cycle Key Discipline Funding from Shanghai Tongji Hospital (No. ZDTS24-RX) and 2025 Cultivation Project for the National Natural Science Foundation of Shanghai Tongji Hospital (GJPY2415).

Data Availability

No datasets were generated or analysed during the current study.

Declarations

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Competing Interests

The authors declare no competing interests.